Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.
At present, there is a lack of high-quality evidence-based measures for perioperative management of bone cancer. Previous studies have mainly been retrospective, with common issues such as missing variables, small sample sizes, and single disease types, making it difficult to systematically reveal perioperative pathophysiological patterns and provide reliable evidence for clinical management. Therefore, high-quality prospective studies are urgently needed.
Therefore, this study intends to conduct a prospective cohort study of patients undergoing surgery for bone cancer, establish a perioperative database, clarify the incidence of complications, explore the factors related to perioperative complications, and provide evidence-based support for improving perioperative management and patient prognosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bone cancer surgery | Procedure | patients receive surgery based on the doctor's discretion and the consideration of the patients and their family |
| Measure | Description | Time Frame |
|---|---|---|
| Complication | This includes embolic events, pulmonary complication, wound complication, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom | hospital discharge, an average of 10 days |
| Measure | Description | Time Frame |
|---|---|---|
| The rate of perioperative transfusion of allogeneic blood products | This includes blood products such as plasma and platelets, erythrocytes | hospital discharge, an average of 10 days |
| Wound drainage volume |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
patients undergoing elective bone cancer resection surgery
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Second Affiliated Hospital of Zhejiang University anesthesiology department | Hangzhou | Zhejiang | 310000 | China |
Not provided
Not provided
Not provided
Not provided
Accumulated postoperative wound drainage volume
| hospital discharge, an average of 10 days |
| The coagulation function tests during the perioperative period | This includes thromboelastography result | hospital discharge, an average of 10 days |
| Hemoglobin levels | Hemoglobin levels during hospitalIzation | hospital discharge, an average of 10 days |
| 6-month mortality | 6 months |
| 1-year mortality | 1 year |
| 2-year mortality | 2 years |
| 3-year mortality | 3 years |